A phase I, multiple-dose study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Dacetuzumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 07 Oct 2011 Actual end date changed from Aug 2007 to Nov 2007 as reported by ClinicalTrials.gov.
- 09 Oct 2008 Genentech reported as a Sponsor by ClinicalTrials.gov.
- 09 Oct 2008 Actual end date was Aug 2007, according to ClinicalTrials.gov.